If you would like to learn more about the IAEA’s work, sign up for our weekly updates containing our most important news, multimedia and more. This publication includes existing experiences, lessons ...

Shares in Actinium Pharmaceuticals have lost almost two-thirds of their value after the FDA asked for a second clinical trial before it would consider reviewing the company's Iomab-B radioligand ...

Actinium's Chairman and CEO, said, "The current era of radiotherapy is built on the clinical and commercial success of Pluvicto in prostate cancer. The field is now looking to address patients ...

Actinium Pharmaceuticals, Inc., a pioneer in the development of targeted radiotherapies, announced it has entered into an agreement for the supply of Actinium-225 (Ac-225) with Eckert & Ziegler. Under ...

Actinium has outlined its expanded market opportunities and expected 2025 milestones for each of its clinical programs as well as its R&D and radiopharmaceutical manufacturing capabilities as ...

Actinium is a pioneer in the development of targeted radiotherapies intended to meaningfully improve patient outcomes. Actinium is advancing its lead product candidate Actimab-A, a CD33 targeting ...